A Study of LY3316531 in Healthy Participants and in Participants With Psoriasis
I9H-MC-FFAA - ClinicalTrials.gov - NCT03418493
The purpose of this study is to evaluate how well LY3316531 is tolerated and what side effects may occur in healthy participants and participants with psoriasis. The study drug will be administered either subcutaneously (SC) (under the skin) or intravenously (IV) (into a vein in the arm).
Trial Summary
Age Range
18 - 64 yearsConditions the trial is for
PsoriasisWhat the trial is testing?
LY3316531-IVCould I receive a Placebo?
YesEnrollment Goal
63Trial Dates
Jan 30, 2018 - Jul 29, 2019How long will I be in the trial?
Your participation could last between 16 and 57 weeks.Trial Phase
ILilly Trial Alerts
Not the right fit? Sign up to receive updates about new trials that are listed or when a new trial site begins enrolling near you.
You will complete the questionnaire on another website.YesNo